Additional ADCs comprise polatuzumab vedotin-piiq, Brentuximab vedotin, tisotumab vedotin-tftv, gemtuzumab ozogamicin, Enfortumab vedotin, Sacituzumab govitecan, Trastuzumab deruxtecan, loncastuximab tesirine-lpyl, Moxetumomab pasudotox, belantamab mafodotin-blmf, and inotuzumab ozogamicin
doi: 10.1016/j.bmc.2016.11.035 Summary Keywords cysteine, cancer, resistance, chemotherapy, post-translational modification Citation Min J-Y, Chun K-S and Kim D-H (2023) The versatile utility of cysteine as a target for cancer treatment
Inclusion of selection criteria that reflect skin conditions other than skin whitening would be more suitable for evaluating each skin condition
Global iodine nutrition: Where do we stand in 2013